Latest Breaking News On - Anurag relan - Page 2 : vimarsana.com

Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)

Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

IsraelJapanAustraliaCanadaAmsterdamNoord hollandNetherlandsLondonCity ofUnited kingdomUnited statesAmericaHeather robertsonAnurag relanEthan metelenisMichael levitan

Pharming Group Announces Development Plans For Leniolisib For Additional Primary Immunodeficiencies (Pids)

Pharming Group Announces Development Plans For Leniolisib For Additional Primary Immunodeficiencies (Pids)
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

LondonCity ofUnited kingdomJapanCanadaAustraliaAmsterdamNoord hollandNetherlandsUnited statesIsraelAmericaAnurag relanMichael levitanGulbu uzelV koneti rao

Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisib - Pharming (NASDAQ:PHAR)

The multinational Phase III study is evaluating a new pediatric granulated formulation of leniolisib in children aged 1 to 6 years with APDS, a rare primary immunodeficiency Leiden, The Netherlands, November 21,

AmsterdamNoord hollandNetherlandsJapanAustraliaLondonCity ofUnited kingdomCanadaUnited statesAmericaHeather robertsonEveline wuMichael levitanClaire dobbsAnurag relan

First patient enrolled in Pharming's trial aimed at treating APDS

The first patient has been enrolled in a phase 3 clinical trial of leniolsib a treatment for a rare inherited condition affecting how the immune system works.

JapanUnited statesTokyoHirokazu kaneganeAnurag relanDevices agencyMinistry of healthDrug administrationDepartment of child healthJapan pharmaceuticalsPharming groupMedical devices agencyChild healthTokyo medicalDental universityUnited states food

Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in Japan

/PRNewswire/ Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the first patient has been enrolled.

JapanTokyoLondonCity ofUnited kingdomAmsterdamNoord hollandNetherlandsUnited statesCanadaAustraliaAmericaHirokazu kaneganeClaire dobbsEthan metelenisHeather robertson